3 takeaways from a European obesity scientific meeting

ConferencepositiveZepboundPositive

AI Analysis

Summary

Eli Lilly presented positive data on its amylin-Zepbound combination for obesity at a European scientific meeting, while Novo Nordisk, AbbVie, and Boehringer Ingelheim also shared updates on their obesity drug candidates.

Outcome Details

Eli Lilly impressed with amylin-Zepbound combination data; Novo demonstrated continued weight loss with oral switch; AbbVie and Boehringer showed contender updates

Importance:5/10

Sentiment:

0.60

obesityweight lossclinical dataEuropean conference

Related Companies

$LLY $NVO $ABBV

Read the original article

Published by BioPharma Dive on October 1, 2026 4:16 PM

Read Original